Unknown

Dataset Information

The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.


ABSTRACT: Among individuals with the rare congenital bleeding disorder hemophilia A, the major challenge is inhibitor formation, which is associated with significant morbidity and cost. Yet, as the optimal approach to prevent and eradicate inhibitors is not known, we are at equipoise. Because classic trial design is not practical in a rare disease setting, we designed 2 48-week randomized trials comparing ELOCTATE and emicizumab to prevent and eradicate inhibitors. To achieve statistical efficiency, we incorporated historic data (Bayesian priors) on inhibitor formation to allow preferential randomization to emicizumab, piecewise exponential survival models to determine mean and 95% confidence interval for inhibitor formation in each arm, and simulations to determine the best model design to optimize

SUBMITTER: Bertolet M 

PROVIDER: S-EPMC7656929 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature